Shanghai WD Pharmaceutical
CompanyChina
Shanghai WD Pharmaceutical develops one asset, in phase 2 (WD-1603 in Parkinson's disease). Mostly small molecule acting on Ddc; based in China.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Extended-release carbidopa-levodopa formulation restoring dopamine levels in the brain.
Phase 2, Small molecule, Ddc, Parkinson's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies6